Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Cytarabine, Daunorubicin, Quizartinib in patients with Acute Myeloid Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.